CMS HIV Testing (Diagnosis) Coverage Policy Update: What Billing Teams Need to Know for 2026
CMS has modified National Coverage Determination (NCD) 53, the long-standing policy governing diagnostic HIV testing under Medicare, with an effective date of March 12, 2026. This update refines the medical necessity framework for HIV diagnostic workups—including serologic assays, antigen testing, and confirmatory methods such as Western Blot—and clarifies the clinical indications that must be documented to support coverage. If your practice or facility bills Medicare for HIV diagnostic services, this policy change warrants a careful review of your documentation workflows before the effective date.
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Human Immunodeficiency Virus (HIV) Testing (Diagnosis) |
| Policy Code | NCD 53 |
| Change Type | Modified |
| Effective Date | 2026-03-12 |
| Impact Level | Medium |
| Specialties Affected | Infectious Disease, Internal Medicine, Primary Care, OB/GYN, Emergency Medicine, Nephrology, Oncology, Neurology |
| Key Action | Audit clinical documentation practices now to ensure HIV diagnostic orders are supported by one or more of the 11 defined indication criteria before claims are submitted. |
What CMS NCD 53 Covers: HIV Diagnostic Testing Under Medicare
The Centers for Medicare & Medicaid Services' NCD 53 governs Medicare coverage for HIV testing performed for diagnostic purposes—that is, to establish or confirm HIV infection in a patient with clinical suspicion of disease. This is distinct from HIV screening, which is covered under separate preventive benefit rules.
The policy recognizes two primary diagnostic approaches. The first is serologic testing, which includes enzyme immunoassays (EIA) formatted to detect HIV-1, HIV-2, or both simultaneously, and capable of detecting both IgM and IgG antibodies. When an initial EIA is repeatedly positive or indeterminate, CMS recognizes the Western Blot as the standard confirmatory method for antibody specificity.
The second approach involves direct viral detection. CMS acknowledges that serologic testing alone may be insufficient in three specific scenarios: acute retroviral syndrome (where the IgG antibody response hasn't yet developed), cases of persistent equivocal results due to viral antigen variability, and perinatal HIV infection, where transplacental passage of maternal HIV antibody can produce false positives. In these cases, laboratory evidence of HIV—via culture, antigen assays, proviral DNA assays, or viral RNA assays—is required.
CMS Medical Necessity Criteria for HIV Diagnostic Testing
This is the section your billing team needs to internalize. Under the updated NCD 53, diagnostic HIV testing is covered when there is strong clinical suspicion supported by documentation of one or more of the following 11 indications:
| # | Covered Indication |
|---|---|
| 1 | A documented, otherwise unexplained AIDS-defining or AIDS-associated opportunistic infection |
| 2 | Another documented sexually transmitted disease indicating significant HIV exposure risk |
| 3 | Documented acute or chronic hepatitis B or C infection indicating significant HIV exposure risk |
| 4 | A documented AIDS-defining or AIDS-associated neoplasm |
| 5 | A documented AIDS-associated neurologic disorder or otherwise unexplained dementia |
| 6 | Another AIDS-defining clinical condition, or a history of severe, recurrent, or persistent conditions suggesting underlying immune deficiency (e.g., cutaneous or mucosal disorders) |
| 7 | Otherwise unexplained generalized signs and symptoms suggestive of a chronic process with underlying immune deficiency—including fever, weight loss, malaise, fatigue, chronic diarrhea, failure to thrive, chronic cough, hemoptysis, shortness of breath, or lymphadenopathy |
| 8 | Otherwise unexplained laboratory evidence of a chronic disease process with underlying immune deficiency—including anemia, leukopenia, pancytopenia, lymphopenia, or low CD4+ lymphocyte count |
| 9 | Signs and symptoms of acute retroviral syndrome: fever, malaise, lymphadenopathy, and skin rash |
| 10 | Documented exposure to blood or body fluids known to be capable of transmitting HIV (e.g., needle sticks and significant blood exposures) where antiviral therapy is initiated or anticipated |
| 11 | The patient is undergoing treatment for rape |
Each of these represents a distinct clinical pathway to coverage. The critical documentation requirement is that the clinical finding must be documented—a provider's suspicion alone, without supporting chart documentation, is unlikely to satisfy medical necessity review.
The p24 Antigen Test: A Coverage Nuance Worth Noting
The HIV-1 core antigen (p24) test detects circulating viral antigen, which can appear before antibodies develop and may also be present in later-stage illness. CMS explicitly notes that the prognostic utility of p24 has been diminished by the development of sensitive viral RNA assays. Its primary clinical use today—as the policy describes it—is as a routine screening tool for potential blood donors.
This distinction matters for diagnostic billing. If your facility is ordering p24 as part of a diagnostic HIV workup rather than a blood-donor screening protocol, the clinical rationale needs to be clearly articulated in the documentation. Without it, you're likely looking at a medical necessity denial.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
Affected Codes
This policy does not list specific CPT or HCPCS codes in the current published version of NCD 53-v3. Facilities should work with their coding team and reference the AMA CPT code set to identify the applicable laboratory codes for HIV antibody testing, Western Blot confirmation, antigen assays, and viral RNA/DNA assays—and ensure those claims are supported by the medical necessity criteria outlined above.
No specific CPT, HCPCS, or ICD-10 codes are enumerated in this policy. Billing teams should consult with their laboratory coding specialists and reference CMS's Medicare Claims Processing Manual for guidance on applicable codes.
What Your Billing Team Should Do
| # | Action Item |
|---|---|
| 1 | Audit your order templates before March 12, 2026. Pull your current HIV diagnostic order sets and confirm that the ordering provider is required to select or document one of the 11 clinical indications outlined in NCD 53. If your EHR doesn't prompt for this, flag it for your IT or clinical informatics team now—not after claims start denying. |
| 2 | Update your ABN workflow for high-risk encounters. For patients who present with exposure risk but whose documentation doesn't clearly satisfy any of the 11 indications, train your front-desk and nursing staff to initiate an Advance Beneficiary Notice of Noncoverage (ABN) before the test is performed. This protects your practice's ability to collect from the patient if Medicare denies. |
| 3 | Differentiate diagnostic testing from screening in your coding. Ensure your coders understand the distinction between diagnostic HIV testing (governed by NCD 53) and HIV screening (governed by separate preventive service coverage rules). Applying a screening diagnosis code to a diagnostic workup—or vice versa—creates both coverage and compliance risk. |
| 4 | Educate your providers on the p24 documentation requirement. If your infectious disease or lab medicine providers are ordering p24 antigen testing as part of a diagnostic—not blood-donor screening—protocol, make sure the clinical rationale is explicitly documented in the chart. The policy's language on diminished diagnostic utility creates audit exposure if this isn't addressed. |
| 5 | Review perinatal and neonatal HIV testing protocols specifically. The policy carves out perinatal HIV infection as a scenario where standard serologic testing is insufficient, requiring direct viral detection. If your OB/GYN or NICU teams have standing order sets for HIV testing in newborns, ensure those orders align with this coverage framework and that the clinical rationale is captured. |
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.